| 1.73 0.01 (0.58%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.15 | 1-year : | 2.3 |
| Resists | First : | 1.84 | Second : | 1.97 |
| Pivot price | 1.8  |
|||
| Supports | First : | 1.64 | Second : | 1.37 |
| MAs | MA(5) : | 1.71 |
MA(20) : | 1.81 |
| MA(100) : | 1.65 |
MA(250) : | 1.57 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19.7 |
D(3) : | 14 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 4.06 | Low : | 0.88 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RPTX ] has closed above bottom band by 28.5%. Bollinger Bands are 90% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.75 - 1.76 | 1.76 - 1.77 |
| Low: | 1.68 - 1.69 | 1.69 - 1.7 |
| Close: | 1.72 - 1.73 | 1.73 - 1.74 |
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Thu, 30 Oct 2025
Here's Why Repare Therapeutics (NASDAQ:RPTX) Must Use Its Cash Wisely - Yahoo Finance
Wed, 29 Oct 2025
Repare Therapeutics Inc. (NASDAQ:RPTX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Mon, 27 Oct 2025
HC Wainwright & Co. Maintains Repare Therapeutics (RPTX) Buy Recommendation - Nasdaq
Mon, 27 Oct 2025
RPTX: Analyst Lowers Target Price While Maintaining Buy Rating | - GuruFocus
Wed, 22 Oct 2025
Repare Therapeutics Announces Phase 1 LIONS Trial Abstract Release - TradingView
Wed, 22 Oct 2025
Repare Therapeutics Unveils Phase 1 LIONS Trial Data - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 2.272e+007 (%) |
| Held by Institutions | 1.2 (%) |
| Shares Short | 644 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1047e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 24.7 % |
| Return on Equity (ttm) | -38.9 % |
| Qtrly Rev. Growth | 250000 % |
| Gross Profit (p.s.) | -71.69 |
| Sales Per Share | -65.39 |
| EBITDA (p.s.) | 1.43551e+007 |
| Qtrly Earnings Growth | -2.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -103 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.72 |
| Dividend | 0 |
| Forward Dividend | 620830 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|